Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

The JAK-STAT signaling pathway plays a central role in signal transduction in hematopoietic
cells, as well as in cells of the immune system. The occurrence in most patients affected by …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

Interferon alfa was first used in the treatment of myeloproliferative neoplasms (MPNs) over
30 years ago. However, its initial use was hampered by its side effect profile and lack of …

The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the
treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first …

Key Clinical Points Essential Thrombocythemia Essential thrombocythemia is associated
with an increased risk of thrombosis and bleeding. Most patients with essential …

Classic Philadelphia-negative myeloproliferative neoplasms (MPN) include polycythemia
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …

One out of ten patients with Philadelphia‐negative myeloproliferative neoplasms (MPN)
develop a second cancer (SC): in such patients we aimed at assessing the survival impact of …

Background Ruxolitinib is approved for patients with polycythemia vera (PV) who are
resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease …